Surface Oncology, Inc is a biotechnology business based in the US. Surface Oncology shares (SURF) are listed on the NASDAQ and all prices are listed in US Dollars. Surface Oncology employs 51 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Surface Oncology
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SURF – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Surface Oncology stock price (NASDAQ: SURF)Use our graph to track the performance of SURF stocks over time.
Surface Oncology shares at a glance
|Latest market close||$7.69|
|52-week range||$4.87 - $14.40|
|50-day moving average||$7.26|
|200-day moving average||$8.63|
|Wall St. target price||$16.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.53|
Buy Surface Oncology shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Surface Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Surface Oncology price performance over time
|1 week (2021-07-17)||N/A|
|1 month (2021-06-28)||2.95%|
|3 months (2021-04-28)||3.92%|
|6 months (2021-01-24)||N/A|
|1 year (2020-07-24)||N/A|
|2 years (2019-07-24)||N/A|
|3 years (2018-07-24)||N/A|
|5 years (2016-07-24)||N/A|
Is Surface Oncology under- or over-valued?
Valuing Surface Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Surface Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Surface Oncology's P/E ratio
Surface Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Surface Oncology shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Surface Oncology's EBITDA
Surface Oncology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $27.3 million.
The EBITDA is a measure of a Surface Oncology's overall financial performance and is widely used to measure a its profitability.
Surface Oncology financials
|Revenue TTM||$89.2 million|
|Operating margin TTM||28.82%|
|Gross profit TTM||$86.3 million|
|Return on assets TTM||9.29%|
|Return on equity TTM||17.63%|
|Market capitalisation||$277.1 million|
TTM: trailing 12 months
Shorting Surface Oncology shares
There are currently 4.3 million Surface Oncology shares held short by investors – that's known as Surface Oncology's "short interest". This figure is 5.8% down from 4.5 million last month.
There are a few different ways that this level of interest in shorting Surface Oncology shares can be evaluated.
Surface Oncology's "short interest ratio" (SIR)
Surface Oncology's "short interest ratio" (SIR) is the quantity of Surface Oncology shares currently shorted divided by the average quantity of Surface Oncology shares traded daily (recently around 1.3 million). Surface Oncology's SIR currently stands at 3.17. In other words for every 100,000 Surface Oncology shares traded daily on the market, roughly 3170 shares are currently held short.
However Surface Oncology's short interest can also be evaluated against the total number of Surface Oncology shares, or, against the total number of tradable Surface Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Surface Oncology's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Surface Oncology shares in existence, roughly 100 shares are currently held short) or 0.1305% of the tradable shares (for every 100,000 tradable Surface Oncology shares, roughly 131 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Surface Oncology.
Find out more about how you can short Surface Oncology stock.
Surface Oncology share dividends
We're not expecting Surface Oncology to pay a dividend over the next 12 months.
Surface Oncology share price volatility
Over the last 12 months, Surface Oncology's shares have ranged in value from as little as $4.87 up to $14.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Surface Oncology's is 1.8426. This would suggest that Surface Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Surface Oncology overview
Surface Oncology, Inc. , a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813, as well as a clinical trial collaboration with Roche Holding AG to evaluate SRF388. Surface Oncology, Inc.
Stocks similar to Surface Oncology
Surface Oncology in the news
First Week of September 17th Options Trading For Surface Oncology
Surface Oncology: A Diverse, But Early Pipeline
ARK Investment Leans Into Biotech and Telecom Holdings
Frequently asked questionsWhat percentage of Surface Oncology is owned by insiders or institutions?
Currently 9.791% of Surface Oncology shares are held by insiders and 55.264% by institutions. How many people work for Surface Oncology?
Latest data suggests 51 work at Surface Oncology. When does the fiscal year end for Surface Oncology?
Surface Oncology's fiscal year ends in December. Where is Surface Oncology based?
Surface Oncology's address is: 50 Hampshire Street, Cambridge, MA, United States, 02139 What is Surface Oncology's ISIN number?
Surface Oncology's international securities identification number is: US86877M2098 What is Surface Oncology's CUSIP number?
Surface Oncology's Committee on Uniform Securities Identification Procedures number is: 86877M209
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy HNC Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert